Sanofi: Oddo BHF maintains 'buy' rating before CMD
(CercleFinance.com) - Oddo BHF maintains its "buy" rating on the Sanofi share with a target price of 94 euros, the day before its CMD, at which it does not expect particularly precise guidelines.
The confirmation of trends in both sales and earnings should be warmly welcomed, says the analyst, noting that the consensus currently expects sales growth of 3.5% over 2019-2025, with EPS growth of 5% over this period.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The confirmation of trends in both sales and earnings should be warmly welcomed, says the analyst, noting that the consensus currently expects sales growth of 3.5% over 2019-2025, with EPS growth of 5% over this period.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.